Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)PRNewsWire • 09/30/25
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the USGlobeNewsWire • 09/29/25
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025GlobeNewsWire • 09/26/25
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapiesGlobeNewsWire • 09/24/25
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to PipelineZacks Investment Research • 09/10/25
Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fitInvezz • 09/09/25
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion rangeMarket Watch • 09/09/25